Enveda Biosciences
1880 S Flatiron Court, Ste K,
Boulder
CO
80301
United States
15 articles about Enveda Biosciences
-
Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million
4/20/2023
Enveda Biosciences announced that it has closed an additional $51 million equity financing to add to the $68 million Series B announced in December 2022.
-
Enveda's primary R&D efforts will focus on inflammation, fibrosis and neurosensory biology within the GI, dermatology and pulmonary therapeutic areas.
-
Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing
12/21/2022
Dimension led the round with multiple new institutional investors and significant participation from current investors; Silicon Valley Bank provided the debt facility.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer
10/25/2022
Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the company’s Chief Medical Officer.
-
Tobias Kind, Leader in Computational Metabolomics, Joins Enveda Biosciences
7/20/2022
Enveda Biosciences, a pioneer in small molecule drug discovery using machine learning and metabolomics to harness the potential of natural products, announced that Tobias Kind, Ph.D., will join the company’s industry-leading data science team as Research Fellow.
-
Enveda Appoints Pharma Veteran Vanitha Sekar as Chief Business Officer
7/14/2022
Enveda Biosciences, a pioneer in transforming small molecule drug discovery by using machine learning and metabolomics to harness the potential of natural products, announced the appointment of Vanitha Sekar, Ph.D., R.Ph., to the newly created position of Chief Business Officer.
-
Enveda Biosciences Appoints Chief People Officer to Support Company’s Rapid Progress
4/21/2022
Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-generation small molecule drugs, today announced the appointment of Robert J. Buckley as its Chief People Officer.
-
Enveda Biosciences to Open Advanced Drug Discovery and Development Center in Boulder, Colo.; Lead Optimization Laboratory in Hyderabad, Telangana, India
4/7/2022
Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry, announced that it will open two new drug discovery and development facilities to support its ongoing efforts to advance novel small molecule drugs.
-
Biopharma and life sciences companies continue to strengthen their executive teams and boards with this week’s Movers & Shakers.
-
Enveda Biosciences Adds Drug Development Leaders to Scale Efforts and Accelerate Progress
3/17/2022
Enveda Biosciences, a leading biotechnology company harnessing nature’s chemistry to develop next-generation small molecule therapies, announced the addition of three leaders to further scale and accelerate its translational drug development efforts.
-
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
BioSpace Movers & Shakers, Oct. 22
10/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Enveda Biosciences Hires New Chief Platform Officer to Scale Its Drug Discovery Operations
10/18/2021
Enveda Biosciences announced today the appointment of a new Chief Platform Officer (CPO), August Allen .